Nisa Leung leads Qiming’s health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages five USD funds and four RMB funds with over USD 2.7 billion in assets and investment in over 220 companies. Prior to joining Qiming, Nisa was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone) and U-Systems (acquired by GE Healthcare). Nisa also worked as Venture Partner for PacRim Ventures, and Softbank/Mobius Venture Capital.

Ms. Leung was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology and Berry Genomics (SZSE:000710). Her other investments include Acea Biosciences, Aeonmed Medical, Alltech Medical, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, VR Medical, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen and New Horizon Bio.

Ms. Leung earned her MBA from Stanford University and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School.